Home > Healthcare > Medical Devices > Diagnostic Devices > Chemiluminescence Immunoassay Market

Chemiluminescence Immunoassay Market Trends

Report ID: GMI9477
Published Date: May 2024
Report Format: PDF

Download Free Sample

Chemiluminescence Immunoassay Market Trends

The field of chemiluminescence immunoassay (CLIA) has undergone significant technological advancements, enhancing its sensitivity, speed, and automation capabilities. These advancements include the introduction of novel assay formats, enhanced instrumentation with advanced optical detection systems, and the development of sophisticated reagents tailored specifically for CLIA applications.
Moreover, automation features have streamlined laboratory workflows, reducing human error and enabling high-throughput analysis. Therefore, these innovations have transformed CLIA into a versatile and indispensable diagnostic tool, with broad applications in clinical laboratories and research settings worldwide.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Chemiluminescence immunoassay industry size was worth USD 9.8 billion in 2023 and is projected to expand at 7.3% CAGR from 2024 to 2032, due to the rising prevalence of chronic conditions, such as cardiovascular diseases, diabetes, cancer, and infectious diseases.

The consumables product segment in the chemiluminescence immunoassay industry is projected to reach USD 8.2 billion by 2032, owing to the growing trend of decentralized healthcare and point-of-care testing.

The CLEIA technology segment in the chemiluminescence immunoassay industry accounted for USD 5.8 billion in revenue in 2023 and is estimated to witness substantial gains between 2024 and 2032, due to their exceptional sensitivity and specificity.

U.S. chemiluminescence immunoassay industry size is anticipated to record USD 6.6 billion by 2032, led by the ongoing progress in diagnostic technologies, especially in immunoassay methods.